GlassScriptPhysician profile
Eduardo D Castillo
NPI 1023035623
$2,848.38
in general payments reported to CMS, 2019-2025
29 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $166 · 2021: $216 · 2022: $499 · 2023: $273 · 2024: $200 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $800.00 | 2019 | |
| Ethicon US, LLC | $364.88 | 2019-2023 | Enseal |
| Intuitive Surgical, INC. | $227.49 | 2022-2023 | Da Vinci Surgical System |
| Micro-Tech Endoscopy USA, INC. | $182.06 | 2019 | |
| Medtronic, INC. | $176.15 | 2022-2025 | Signia, Ligasure |
| Medical Device Business Services, INC. | $125.00 | 2021 | |
| Sirtex Medical INC | $111.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.42 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.73 | 2020-2021 | |
| Braintree Laboratories, INC. | $70.45 | 2019-2025 | Suflave |
| Acera Surgical, INC. | $66.13 | 2025 | Restrata Wound Matrix |
| Acell, INC. | $58.75 | 2019-2020 | |
| Integra Lifesciences Corporation | $48.47 | 2022-2024 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Innovation Technologies INC | $45.74 | 2023 | Irrisept |
| Ferring Pharmaceuticals INC. | $44.88 | 2022-2025 | Rebyota |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.92 | 2019 | |
| Concordia Pharmaceuticals INC. | $38.99 | 2019 | |
| Axonics, INC. | $35.46 | 2021-2022 | |
| Convatec INC. | $30.86 | 2019-2023 | |
| Kerecis Limited | $28.35 | 2022 | |
| Davol INC. | $28.32 | 2023 | Phasix Mesh |
| Thd America, INC. | $28.30 | 2023-2024 | |
| Janssen Biotech, INC. | $21.85 | 2023 | Stelara, Remicade, Simponi Aria |
| Lilly USA, LLC | $20.73 | 2024 | Omvoh |
| Mimedx Group, INC. | $18.33 | 2025 | |
| Merck Sharp & Dohme LLC | $15.76 | 2019 | |
| Tela Bio, INC. | $15.61 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Smith+Nephew, INC. | $15.44 | 2021 | |
| Polynovo North America LLC | $15.43 | 2024 | Novosorb Btm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.